Treatment of early and mid-term primary biliary cirrhosis by Qingying Huoxue Decoction Combined ursodeoxycholic acid: a clinical observation / 中国中西医结合杂志
Chinese Journal of Integrated Traditional and Western Medicine
; (12): 290-293, 2015.
Article
in Zh
| WPRIM
| ID: wpr-297438
Responsible library:
WPRO
ABSTRACT
<p><b>UNLABELLED</b>OBJECTIVE To observe the clinical efficacy by Qingying Huoxue Decoction (QHD) combined ursodeoxycholic acid (UDCA) in treating patients with early and mid-term primary biliary cirrhosis (PBC). METHODS Totally 78 patients were randomly assigned to the treatment group and the control group, 39 in each group. All patients received basic treatment and took UDCA (at the daily dose of 13-15 mg/kg). Patients in the treatment group took QHD, one dose per day. The treatment course for all was 6 weeks. Clinical efficacy, gamma-glutamyl transferase (γ-GGT), alkaline phospatase (ALP), TBIL, alanine aminotransferase (ALT), and aspartate transaminase (AST) were observed before and after treatment. RESULTS Totally 21 (53. 8%) patients obtained complete response in the treatment group, with statistical difference when compared with that of the control group (11 cases, 30. 8%). Levels of GGT, ALP, ALT, AST, and TBIL decreased in the two groups after treatment (P < 0.01). Levels of ALP, GGT, and TBIL were obviously lower in the treatment group than in the control group (P < 0.05).</p><p><b>CONCLUSIONS</b>QHD combined UDCA in treating early and mid-term PBC patients was superior to the effect of using UDCA alone. It also could improve patients' liver function.</p>
Full text:
1
Database:
WPRIM
Main subject:
Aspartate Aminotransferases
/
Ursodeoxycholic Acid
/
Drugs, Chinese Herbal
/
Therapeutic Uses
/
Alanine Transaminase
/
Drug Combinations
/
Drug Therapy
/
Gamma-Glutamyltransferase
/
Liver Cirrhosis, Biliary
/
Metabolism
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Integrated Traditional and Western Medicine
Year:
2015
Document type:
Article